Eva Medvedova is a Hematology physician affiliated with Oregon Health & Science University. OpenAlex indexes 102 publications with 1,918 citations (h-index 16).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3181 SW Sam Jackson Park Rd
Ohsu Knight Cancer Institute Mail Code Cr145
Portland, OR 972393011
Telephone
503-494-7999Registry record last updated 3 Jan 2018.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GENZYME CORPORATIONProgram year20251 payment
- GENZYME CORPORATIONProgram year20241 payment
- Janssen Research & Development, LLCProgram year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
29.4%Thalidomide Analog24.7%Lenalidomide55%Revlimid38%Pomalyst8%Part D<11 patientsProteasome Inhibitor2%Ninlaro100%Part D<11 patients+ 2 more classes in this area
Dermatology
22.1%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor22.1%Acyclovir100%Part D≥76 patientsNervous system
16%Gabapentinoids4.4%Pregabalin53%Gabapentin47%Part D<11 patientsSNRI3.4%Duloxetine Hcl100%Part D≥11 patients+ 4 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab
New England Journal of Medicine
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Eric Orwoll, MD
Oregon Health & Science University
Aaron Caughey, MD
Oregon Health & Science University
Tomasz Beer, MD
Oregon Health & Science University
John Nutt, MD
Oregon Health & Science University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”